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In a rapidly expanding population of patients with chronic kidney disease, including 2 million people 
requiring renal replacement therapy, cardiovascular mortality is 15 times greater than the general 
population. In addition to traditional cardiovascular risk factors, more poorly defined risks related to 
uraemia and it’s treatments appear to contribute to this exaggerated risk. In this context, the 
microcirculation may play an important early role in cardiovascular disease associated with chronic 
kidney disease. Experimentally the uraemic environment and dialysis have been linked to multiple 
pathways causing microvascular dysfunction.  Coronary microvascular dysfunction is reflected in 
remote and more easily studied vascular beds such as the skin. There is increasing evidence for a 
correlation between systemic microvascular dysfunction and adverse cardiovascular outcomes.  
Systemic microcirculatory changes have not been extensively investigated across the spectrum of 
chronic kidney disease. Recent advances in non-invasive techniques studying the microcirculation in 
vivo in man are increasing the data available particularly in patients on haemodialysis.  Here, we 
review current knowledge of the systemic microcirculation in dialysis populations, explore whether 
non-invasive techniques to study its function could be used to detect early stage cardiovascular 
disease, address challenges faced in studying this patient cohort and identify potential future 
avenues for research.  
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Introduction 
Systemic microvascular dysfunction has been associated with increased cardiovascular morbidity 1, 2 
and mortality3, 4. This association is potentially being driven by shared underlying pathological events 
instrumental in both macro and microvascular disease. Persistent changes in vascular tone lead to 
structural remodelling. Repeated activation of the vascular endothelium by pro-atherogenic insults 
results in an imbalance in the production of  vasoactive substances, inflammation and a pro-
thrombotic state5. In combination, these changes compromise the structural and functional ability of 
the microcirculation to compensate for fluctuating demands.  
It is in the coronary circulation, where up to 80% of overall resistance resides in the microvessels6,   
that dysfunction has been most convincingly linked to clinically relevant outcomes. The presence of 
coronary microvascular and endothelial dysfunction not only predicts subsequent cardiovascular 
events 7-9, but themselves constitute the first stage of atherosclerotic coronary artery disease10, 11. 
Up to 40% of patients referred for angiography following ‘typical cardiac chest pain’ are found to 
have normal epicardial coronary arteries12. These patients can be assumed to have a combination of 
functional and structural coronary microvascular disease contributing to abnormal myocardial 
perfusion. 
This impairment of coronary microvascular structure and function is reflected in concurrent changes 
in remote and more easily studied vascular beds.  For example significant reductions in dermal 
capillary numbers have been demonstrated in patients with ‘typical cardiac chest pain’ despite 
normal coronary arteries13. Peripheral microvascular dysfunction has therefore been used as a 
surrogate for dysfunction of the coronary microcirculation.  
There are a growing number of novel methods being utilised to study the structure and function of 
the systemic microcirculation in vivo in multiple patient cohorts, including those with chronic kidney 
disease14. 
 
Why study the microcirculation in end stage renal disease? 
The global prevalence of chronic renal disease is upwards of 13%15 and more than 2 million people 
worldwide are dependent on renal replacement therapies16. In this population, rates of 
cardiovascular mortality are 15 times those of the general population17.  Although traditional 
cardiovascular risk factors are prevalent within the dialysis population their presence alone does not 
fully account for this exaggerated risk18. In this context, systemic microcirculatory dysfunction may 
be a significant contributor to cardiovascular burden. 
Patients with end stage renal disease who are on dialysis are at significant risk for systemic 
microvascular dysfunction. Uraemia is associated with endothelial cell activation19, impaired 
endothelial repair20, oxidative stress21 and impaired nitric oxide bioavailability. Additionally, these 
patients exist in a state of chronic inflammation22.  Levels of inflammatory mediators such as 
Interleukin-6 and tumour necrosis factor are strongly correlated with eGFR23, both are associated 
with endothelial dysfunction24, 25. Other dialysis specific risk factors include repeated myocardial 
stunning and haemodynamic perturbation of vascular beds26 during haemodialysis and exposure to 
non-physiological dialysis fluids in peritoneal dialysis26. 
Multiple studies have demonstrated links between surrogate markers of endothelial dysfunction and 
chronic renal disease . These include; circulating endothelial surface layer components27, markers of 
inflammation and amino acids released by the endothelial cells in response to damage 28, 29, peptides 
known to inhibit pro-atherogenic changes30 and endothelial dysfunction as measured in larger 
vessels31.  
The systemic microcirculation in dialysis patients 
Techniques that directly and non-invasively study in vivo alterations in microvascular structure 32, 33 
and function 28, 34-36 are increasingly being used to expand our knowledge of the relationship 
between chronic renal disease and microcirculatory dysfunction. Perturbation of microvascular 
function in patients with chronic renal disease has been reproducibly demonstrated in different 
vascular beds, including skin28, 36, 37, sublingual27, 32, 38 and coronary39.  
Cutaneous Microcirculation 
The cutaneous microcirculation, the most easily accessible vascular bed, has been of interest in 
patients on dialysis since histological alterations were first demonstrated in these patients in the 
1980s. Skin biopsies from haemodialysis patients without known macrovascular disease or diabetes 
demonstrated thickening of the basement membrane, endothelial activation and chronic 
inflammatory cell infiltrates in cutaneous capillaries 40. The extent of these changes correlated with 
the length of time these patients had been on haemodialysis41. In vivo the nail-fold capillary bed is 
easily visualised microscopically. Morphological changes here have also been correlated with 
duration of dialysis 42. Reduction in capillary numbers is important as it reduces the surface area 
available for exchange, jeopardising tissue health. Capillary rarefaction has been demonstrated in 
the nail-fold capillaries of  paediatric haemodialysis patients 33 compared with healthy, ‘height-age’ 
matched controls. The paediatric population is interesting to study with regards the microcirculation 
as unlike their adult counterparts, they often have a single renal limited pathology. This helps to 
differentiate microcirculatory pathology attributable to uraemia and it’s treatments from that 
attributable to other systemic pathologies for example diabetes.  This finding has been replicated in 
adult haemodialysis cohorts43, 44 well matched for age, blood pressure and BMI with healthy 
controls. 
Due to its role in temperature regulation, human skin has a high vasodilatory reserve and can change 
its flow more than a hundred-fold in response to metabolic, thermal and pharmacologic stimuli. 
Relative changes in skin blood flow can be easily and non-invasively measured using laser Doppler 
based techniques45 (Figure 1). Even in the resting state oscillations in microvascular flow are 
modulated by multiple physiological factors. Spectral analysis can be used to sub-divide laser 
Doppler acquired recordings according to their frequency into those representing; endothelial 
activity, sympathetic activity, vascular myogenic activity, respiratory activity and heart activity 14. 
Reports of baseline skin blood flow in dialysis patients did not initially seem to be significantly 
different to healthy controls28, 34, 46-48. However, when examined in more detail subtle differences 
were apparent. Although the averaged flux was not different, ‘hot spots’ or distinct spots of high 
perfusion were reduced and significant impairments were noted in the frequency domains 
corresponding to endothelial, sympathetic and cardiac activity in dialysis patients compared with 
controls36.  
Maximal vasodilation of skin blood vessels can be achieved by localised heating to between 42-44°C 
49. A reactive hyperaemia can also be provoked by a brief period of arterial occlusion50 (Figure 2). 
Impairments in the maximal vasodilatory response to heating36, 46 and maximal post-occlusive flow28, 
36 have been reported in haemodialysis patients compared with healthy controls.  
 In their study of 63 haemodialysis patients and 33 healthy controls, Stewart and colleagues36 
reported a delay in the maximal vasodilatory response to heating in the dialysis patients compared 
with controls. However, they were only able to demonstrate a significant reduction in the size of the 
maximal post-occlusive flow compared with controls in those haemodialysis patients with known 
diabetes and cardiovascular disease, not the cohort as a whole. A smaller study (16 haemodialysis 
patients versus 16 controls)28, wherein all participants were ‘free of concomitant diseases causing 
alterations in endothelium-dependant vasomotion’, did report a reduction in maximal post-occlusive 
flow in the dialysis cohort compared with controls. As would be expected, their dialysis group was 
significantly more hypertensive than their healthy controls and given that even borderline 
hypertension effects the microcirculation this may have contributed to the microvascular 
dysfunction observed. 
More direct interrogation of this apparent reduction in microvascular function can be achieved by 
combining laser Doppler measurements with iontophoretic application of vasoactive substances  51 
(Figure 3) to investigate which discreet areas of microvascular function are impaired. Impairments of 
both endothelial-dependant and -independent responses have been demonstrated in haemodialysis 
patients compared with both age, sex and BMI matched healthy controls28, 34 and pre-dialysis chronic 
renal disease patients with comparable cardiovascular burden52.  
Sublingual Microcirculation 
More recently SDF imaging has allowed for direct visualisation of flow in other vascular beds with a 
mucosal covering. The most commonly studied is the sublingual bed 53, 54 (Figure 4 a + b). To date the 
only publish study using SDF to examine chronic changes in sublingual vessel density and flow in 
dialysis patients32, reported a reduction in total and perfused vessel density plus increased vessel 
flow heterogeneity compared with controls. This was particularly pronounced in the very small 
vessels (diameter less than 20µm)32.  
Assessment of the sublingual circulation also provides an opportunity to non-invasively assess 
another component of the vascular system, the glycocalyx.  The glycocalyx covers the luminal 
surface of endothelial cells. It is a negatively charged network of proteoglycans, glycosaminoglycans 
and plasma constituents, which acts as an interface between the blood and the vascular wall.  The 
glycocalyx has important regulatory and protective roles including, regulating vascular wall 
permeability, mechano-transduction, and inhibiting leucocyte adhesion. It is susceptible to damage 
from oxidative stress, which may arise from inflammation, ischaemia, hyperglycaemia, or other 
causes55.  Due to its delicate nature, study of the glycocalyx is challenging. Historical approaches 
have included measurement of total volume using tracers, and measuring shed glycocalyx 
components in plasma. SDF-acquired images (Figure 4b) can now be combined with Glycocheck 
software to analyse spatial and temporal variations in erythrocyte column width within the 
microvasculature56. When the cell-impermeable glycocalyx is damaged, circulating red cells can 
travel closer to the endothelium. Using this approach, loss of glycocalyx barrier properties has been 
demonstrated in a mixed cohort of haemodialysis and peritoneal dialysis patients 27, and has been 
found to associate with diminished eGFR and with increased circulating levels of shed endothelial 
surface layer components syndecan-1 and thrombomodulin 38.  
Coronary Microcirculation 
The ability of the coronary microcirculation to adapt to changing demands is vital. Coronary flow 
reserve is the maximum flow resulting from stress vasodilatation of coronary arteries and the 
coronary microcirculation, measured using positron emission tomography or magnetic resonance 
imaging. In this context, 90% of myocardial blood flow takes place through vessels with diameter 
less than 150µm, which penetrate the walls of the myocardium 57. Coronary flow reserve is therefore 
a test of both endothelial dysfunction and coronary microvascular reserve. It is expressed as the 
ratio of hyperaemic to basal diastolic peak velocities, with a value above two considered normal. 
Low coronary flow reserve indicates a reduced ability to appropriately increase flow in response to 
increased oxygen demand. Coronary flow reserve has been found to be significantly lower in dialysis 
patients compared with healthy controls who were well matched for age, sex, BMI and  blood 
pressure 39, 58. In patients with angiographically normal coronary arteries, 50% of the dialysis cohort 
were found to have coronary flow reserve less than 2 compared with only 5% in the control group of 
non-dialysis patients 39. 
Potential confounding factors 
Caution must be exercised in attributing all the alterations observed in the above studies to renal 
failure and its treatments. Many patients with end stage kidney disease have co-morbid illnesses 
which may also affect the systemic microcirculation, most notably hypertension and diabetes 
mellitus. Several of the studies discussed above exclude from their control group of ‘healthy 
volunteers’ those with these conditions but hypertension, diabetes and other co-morbidities are 
present in a large proportion of the dialysis group32, 36.  In these studies, measured differences 
between groups are likely to represent the combined effects of chronic uraemia, dialysis and other 
co-morbidities.  
Even in otherwise well matched cohorts, dialysis patients frequently have increased systolic blood 
pressure compared with their control counterparts32, 33. Therefore, in addition to their dialysis 
patients and healthy controls, Farkas and colleagues studied a third group of age-matched patients 
with essential hypertension28. They were able to demonstrate a significant reduction in both 
endothelium-dependant and independent vasodilatation in their dialysis patients compared with 
controls and those with hypertension.  
Are microcirculatory changes associated with clinical outcomes? 
A link between microvascular dysfunction and adverse cardiovascular outcomes has been 
demonstrated in other populations 3, 4, 59, 60. Vascular dysfunction in the skin has been demonstrated 
to correlate with coronary disease61 and be an independent marker for cardiovascular disease in 
patients with Type 2 diabetes62. As these techniques become better understood and increasingly 
used in renal cohorts, interest has turned to how they may be used as biomarkers to identify high 
risk patients and facilitate intervention at an earlier stage.  
Coronary microvascular rarefaction has been postulated as contributory to sudden cardiac death in 
the dialysis population63. In a cohort study of nearly 4000 individuals encompassing the whole 
spectrum of chronic renal disease , coronary flow reserve was shown to be strongly associated with 
cardiovascular death independent of chronic renal disease stage64. Adjusting for coronary flow 
reserve in chronic renal disease 4,5 and dialysis-dependant groups attenuated their risk of 
cardiovascular death by 10%, supporting the concept that coronary microvascular dysfunction may 
underlie some of the increased mortality associated with chronic renal disease.  
In separate multi-variate regression analyses, microvascular impairment as measured by forearm 
post-ischaemic vasodilatation 65 and coronary flow reserve 63 were found to be independently 
associated with all-cause mortality in haemodialysis patients.  
Microvascular dysfunction of the coronary and peripheral circulations have also been correlated 
with outcome measures known to have negative prognostic implications such as 
hypoalbuminaemia66, 67 and right ventricular dysfunction68.  
Chronic renal disease mineral bone disease can cause large vessel calcification, a strong predictor of 
cardiovascular death in haemodialysis patients69.  There is some evidence for an association 
between large vessel calification and microvascular dysfunction in haemodialysis patients, those 
with femoral artery calcification exhibited lower maximal vasodilatory responses to ACh and SNP 
than both controls and haemodialysis patients without large vessel calcification 34. There is also 
increasing evidence of a relationship between markers of worsening chronic renal disease mineral 
bone disease and microvascular abnormalities in the absence of large vessel calcification. Dermal 
capillary rarefaction and impaired coronary flow reserve have been associated with increasing levels 
of both iPTH33 and phosphorous 43, 64 in chronic renal disease cohorts. Even in cohorts with normal 
renal function serum phosphate concentrations have been negatively correlated with postocclusive 
capillary recruitment70 and endothelial dysfunction in larger vessels71.  
Patients at risk of other non- cardiovascular disease outcomes which significantly impact on 
morbidity and quality of life, such as wound healing have also been identified using these 
techniques.  Those patients with lower skin blood flow both before and during haemodialysis, as 
measured by laser Doppler, have been shown to be at greater risk of developing wounds and skin 
defects66. All patients in this study who later went on to develop a skin defect had evidence of 
intradialytic ‘critical perfusion’ at the microvascular level in at least one measured area, although 
none exhibited intra-dialytic hypotension. 
What are the effects of chronic dialysis? 
Cardiovascular risk increases as patients progress through the stages of chronic renal disease 
(classified as stages 1 to 5 with progressive falls in glomerular filtration rate and increasing 
albuminuria) and with time on dialysis72. Is microvascular impairment similarly related to stage of 
chronic renal disease and time on dialysis? 
It has been found that even the creation of an arteriovenous fistula in preparation for haemodialysis 
may have systemic microvascular effects. In pre-dialysis patients, successful formation of an 
arteriovenous fistula  led to a reduction in endothelial dependant vasodilation in the fistula arm. 
Following fistula creation, these patients also exhibited a reduction in non-endothelium dependant 
vasodilation in the contralateral arm, indicating that localised changes to the structure of the 
macrocirculation can lead to widespread changes in the microcirculation. This was in contrast to 
those patients who had primary arteriovenous fistula  failure, who exhibited no recordable local or 
systemic changes73. 
Cross-sectional studies also provide evidence for a relationship between stage of kidney disease and 
microcirculatory dysfunction. Plasma levels of shed glycocalyx components such as syndecan-1 and 
markers of endothelial activation such as angiopoietin-2 correlate inversely with eGFR 38. Retinal 
microvessels also narrow progressively with each stage of chronic kidney disease74. Additionally, 
histopathological evidence of endothelial activation and infiltration by inflammatory cells in dermal 
capillaries 40, 41 and circulating levels of adhesion molecules such as sVCAM-1 correlate with duration 
of dialysis 75. The potential effects of renal replacement therapy itself on the microcirculation remain 
less well defined.  Using SDF technology, Dane and his colleagues were able to demonstrate 
impaired glycocalyx integrity associated with worsening eGFR.    However, in their end stage renal 
disease group (n=23) no statistically significant difference was seen between the dialysis patients 
(n=9) and patients with end stage renal disease who were not on dialysis(n=14)38. Common to many 
of the studies presented here small sample size may have contributed to the lack of statistically 
significant findings.  
A large American cohort study found that although coronary microvascular function assessed by 
coronary flow reserve was 23% lower in dialysis patients compared with controls with preserved 
kidney function, this reduction occurred early in chronic kidney disease, with a nadir being reached 
in chronic renal disease stage  464. The authors found no additional reductions in stage 5 or 5D. 
However, it is important to note that the chronic kidney disease stage 4 patients were on average 10 
years older than the dialysis group and had a higher incidence of known ischaemic heart disease and 
oral nitrate use. It is possible in light of this that survivor bias has limited the apparent extent of 
microvascular dysfunction detected in the patients with chronic kidney disease stage 5 in this 
retrospective study. Some of these issues could be addressed by longitudinal studies directly 
investigating microvascular function in dialysis cohorts. INTHEMO is an ongoing two-year study 
primarily designed to assess the effects of haemodialysis intensity on micro and macrovascular 
parameters76. In a preliminary report, these investigators found no statistically significant change in 
glycocalyx parameters at 6 months follow-up compared with baseline. They did however note 
significant heterogeneity in the degree and direction of change of calculated glycocalyx properties at 
6 months, and data at study completion is awaited. One important limitation of historical studies 
may be the effect of the haemodialysis procedure itself. The microcirculation is inherently dynamic, 
and as described below, timing of microvascular measurements with regards to the patients 
haemodynamic therapy itself may have significant impact on results. Standardisation of timing of 
measurements with respect to haemodialysis therapy is an important consideration for future 
studies. 
What are the acute effects of dialysis? 
Haemodialysis has been shown to cause varying degrees of macrohaemodynamic instability in 
patients often because of ultrafiltration of fluid, observed clinically as intradialytic hypotension. 
Recurrent intradialytic hypotension is considered to have negative prognostic implications77. Studies 
of the sublingual microcirculation using SDF during a single haemodialysis session have 
demonstrated a reduction in microvascular flow and decrease in the proportion of the 
microcirculation that is perfused through the course of the treatment78, 79. This reduced flow in all 
microvessels has been attributed to a reduction in circulating volume secondary to ultrafiltration.  In 
some studies, reduced microvascular perfusion has been demonstrated in patients undergoing 
isolated ultrafiltration but not in those undergoing haemodialysis with linear ultrafiltration 80. This 
finding is supported by data showing the reduced flow may be partially corrected by a manoeuvre 
designed to increase central venous filling78. These microcirculatory changes were independent of 
macrohaemodynamic changes, for example blood pressure, implying an element of compensation 
by the microcirculation.  
Decreased intradialytic perfusion has also been demonstrated in the peripheral circulation 66, 81. 
However, it has been suggested that changes in perfusion here may be dependent on the patient’s 
pre-dialysis volume status. Hypervolaemic patients who were ultrafiltrated to normovolaemia had 
improved skin perfusion82, this was accompanied by a decrease in arterial and venous pressure and 
proposed to be as a result of decreased myogenic response as a local auto regulatory effect. Another 
potential mechanism could be interstitial fluid removal with reduced external compression of 
vessels.  
Significant alterations in haemodynamics and shear stress result in stimuli noxious to the glycocalyx 
including oxidative stress83 and inflammation84. An increase in plasma shed glycocalyx constituents 
has been demonstrated over the course of a 4 hour dialysis session. However, this was not 
accompanied by a deterioration in sublingual glycocalyx parameters, potentially reflecting 
differential responses to haemodialysis in different vascular beds 85. Importantly, the reliability of 
plasma shed endothelial components as a marker of endothelial damage in patients with significant 
renal impairment has been challenged, due to decreased renal excretion and unknown dialysis 
clearance86. 
It has been suggested that haemodialysis may not be entirely detrimental to the microcirculation. 
The process of haemodialysis results in the release of local vasodilatory substances 87 and removal of 
circulating inhibitors of endothelial function such as; asymmetrical dimethylarginine, an inhibitor of 
endothelial NO production88, 89. Improvements in retinal microvascular function during single 
haemodialysis sessions have been demonstrated in several studies 90, 91. However, these potentially 
beneficial effects appear to be transient, returning to baseline within hours 88, 92. This may however 
help to explain some of the heterogeneity in the literature and highlights the importance of timing of 
investigations with regards dialysis therapy when designing and evaluating data in studies of the 
microcirculation. 
Is microcirculatory dysfunction modifiable? 
As there is evidence of a relationship between microcirculatory function and eGFR38, 41 it could be 
postulated that successful restoration of excretory function should improve microcirculatory 
parameters.  Renal transplantation is the preferred mode of renal replacement therapy for all 
eligible patients as cardiovascular outcomes and quality of life are improved compared with dialysis.   
Early skin biopsy studies indicated that ‘uraemia associated microangiopathy’ could be at least 
partially reversed by successful transplantation93. Using data and samples from a large biobank, a 
retrospective study of patients receiving their first renal transplant having previously been on 
dialysis, found that sVCAM-1 levels (a marker of endothelial injury) fell within 1 month of 
transplantation and continued to decline for at least 2 years75 supporting an improvement in 
endothelial function with improvement in renal function.  
Cross-sectional studies using SDF imaging in the sublingual circulation have demonstrated significant 
deterioration in glycocalyx and microvascular perfusion parameters in dialysis patients compared to 
age matched healthy controls and renal transplant recipients32, 38. At a median of 5 years post-
transplant, the glycocalyx parameters of patients with a stable functioning transplant were 
indistinguishable from the healthy controls38. Whilst microvascular flow was more heterogeneous in 
transplant recipients the total density of small vessels and the proportion that were perfused was 
not significantly worse than controls32. In the coronary microcirculation transplant recipients were 
found to have a significantly reduced coronary flow reserve compared with healthy controls (1.89 ‘v’ 
2.65), but better than a group of age matched haemodialysis patients (1.57) 58.  
In those with a failing or failed transplant the relationship appears to be more complex. Transplant 
recipients with evidence of interstitial fibrosis and tubular atrophy had sublingual glycocalyx 
parameters comparable to haemodialysis patients despite their median eGFR of 22ml/min38. 
Furthermore, patients who return to dialysis after a failed transplant exhibited worse coronary 
microvascular function than dialysis (both haemodialysis and peritoneal dialysis) patients of similar 
vintage who have never been transplanted67, 94. The known association between inflammation and 
microvascular dysfunction76 led the authors to speculate that inflammation associated with the 
failed allograft was partially responsible for the deterioration, in both these studies the failed 
transplant recipients had higher inflammatory markers than the transplant naïve group. This is an 
interesting hypothesis although the underlying pathology is likely to be multifaceted. While time on 
dialysis may have been similar between groups the patients with failed transplant are likely to have 
had a longer period with end stage renal failure, additionally they will have been exposed to 
immunosuppressant medications such as calcineurin inhibitors, with known vascular effects95. As 
discussed above, changes to the microcirculation occur throughout the stages of chronic renal 
disease and what is not clear from this study is how changes in the failing transplant group compare 
to patients with a native eGFR of 22ml/min.    
 
 
Issues in the current literature 
Comparison of studies in this area is impeded by methodological issues. By its nature the 
microcirculation exhibits significant temporal and spatial heterogeneity 81. Consequently, most of 
the techniques outlined above have to contend with substantial intra-subject variability.  Much of 
the literature reviewed here is cross-sectional therefore there will be significant variability in the 
outcome measures, reducing their ability to detect small differences between patient groups for 
example.  
There are other experimental issues pertinent to studying a renal cohort. End stage renal disease is a 
phenotype, not a specific pathology and therefore renal cohorts are also heterogeneous. Secular, 
geographic, and ethnic variation impact prevalent primary and co-morbid pathologies, many of 
which have direct relevance to the microcirculation such as diabetes and hypertension.  There is also 
high usage in this population of medications known to impact microvascular reactivity. 
Studying patients undergoing an intermittent therapy, such as haemodialysis, presents its own 
challenges; as outlined above, timing of investigations is important, this varies both between and 
within studies 36.  Rapidly changing flow and haematocrit, changes in room and dialysate 
temperature, different compositions of dialysate and method of vascular access are all likely to 
affect the results of these non-invasive techniques. Perhaps more importantly, such a 
haemodynamic insult is likely to affect each vascular bed differently.  
These inherent methodological issues are often compounded by small sample sizes. 
Potential future work 
The issues identified above mean several gaps remain in our knowledge with regards the state of the 
microcirculation as measured using these non-invasive techniques. What is required to adequately 
delineate the natural history of microvascular dysfunction in chronic kidney disease and dialysis are 
large-scale, longitudinal studies in a variety of vascular beds with consensus on timing of 
investigations.  
Along with the heterogeneous nature of a renal cohort there are also several treatment options 
available for renal replacement therapy. The two main forms of dialysis offered to patients, 
haemodialysis and peritoneal dialysis, are intrinsically different and likely to affect the systemic 
microcirculation in distinct ways. As a result of its acute haemodynamic effects and by virtue of the 
fact that they account for the large majority of the dialysis population, most microvascular work in 
dialysis patients has, to date, focused on haemodialysis. Studies investigating microcirculatory 
properties in peritoneal dialysis patients lag behind their haemodialysis contemporaries. When 
peritoneal dialysis patients are included in cohorts they are often analysed with the haemodialysis 
patients under the umbrella of ‘dialysis requiring’. Attempts to analyse them as a sub-group are 
undermined by small numbers27. 
Peritoneal dialysis has been demonstrated to have cardiovascular effects18 but they are both 
qualitatively and quantitatively different from those of haemodialysis. There are also other 
challenges unique to peritoneal dialysis which need examining, most notably the effect of absorbed 
glucose. There is a body of work examining the effects of peritoneal dialysis fluid variants on 
macrohaemodynamic measures such as blood pressure and cardiac output87, 96, 97. Similar work 
examining effects on the microcirculation could allow intervention at an earlier stage in the 
pathological process. The functionality of peritoneal dialysis is largely dependent on the structure 
and integrity of the peritoneal microcirculation. Are there insights to be gained from the systemic 
microcirculation that may increase understanding and aid preservation of the peritoneal 
circulation42, 98?  
Despite these gaps in knowledge there is increasing evidence of microcirculatory dysfunction in 
dialysis cohorts that precedes large vessel disease and is associated with morbidity and mortality. 
This dysfunction appears to be the result of multiple insults including; uraemia and it’s consequences 
i.e. chronic renal disease, mineral bone disease; co-morbid pathologies such as hypertension and 
diabetes and renal replacement therapy itself. This should emphasise to the clinician the importance 
of primary preventative strategies already enshrined in clinical practice such as dialysis adequacy 
targets, stringent blood pressure control and correction of bone mineral abnormalities. Greater 
insights into the pathophysiology of microvascular dysfunction in these patients could advance 
clinical care of dialysis patients in several ways. It could improve our understanding of the potential 
benefits of commonly used medications such as ACE inhibitors, routinely used in proteinuric renal 
disease, there is evidence for a protective effect on systemic vascular endothelium in animal models 
of aging99 and heart failure100. It could help us understand how best to administer renal replacement 
therapies for example the potential benefits of more ‘extended’ haemodialysis76. It could also aid 
development of more novel therapies aimed at protecting endothelial function such as eNOS 
transcriptase enhancers101.   
Conclusion 
The importance of the microcirculation in systemic diseases is becoming increasingly apparent. 
Historically study of the microcirculation in patients with renal disease especially those on dialysis 
has lagged behind other chronic conditions. Difficulties in studying a heterogeneous patient group 
on intermittent therapies may have contributed to this disparity.  
Studies have been small and largely cross-sectional. More traditional techniques for studying the 
microcirculation were often cumbersome and time consuming reducing their clinical utility. We are 
now gaining greater understanding of the role of newer, more patient friendly techniques such as 
SDF imaging which should allow expansion of participant numbers. 
Reproducible differences in microvascular structure and abnormal function have been demonstrated 
in multiple vascular beds in dialysis patients compared with controls. The exact nature and 
chronology of these changes are yet to be fully defined. 
As we anticipate an ever-expanding chronic renal disease population with its disproportionate 
cardiovascular burden, a greater understanding of this dysfunction becomes increasingly important. 
Large scale longitudinal studies are required to achieve this with the hope that the knowledge 
gained will guide future interventions to abrogate cardiovascular risk for these patients.  
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Figure 1 Schematic representation of the principles of Laser Doppler measured flux.    
Laser Doppler technology measures blood flow in the microcirculation to a tissue depth of typically 
1mm. Measurements are based on the Doppler principle whereby monochromatic light changes  
wavelength when it is reflected by moving objects, in this case red blood cells. The magnitude and 
frequency of the changes in wavelength are related to the number and velocity of the moving cells, 
termed red blood cell flux47.   
Figure 2 Representative laser Doppler trace obtained before, during and after a brief period of 
arterial occlusion. 
A reactive hyperaemia can be induced by a brief period of arterial occlusion using a cuff placed 
around the upper arm or leg. This response takes the form of a post-ischaemic flow initially many 
times faster than normal followed by exponential decay to baseline54. This is a complex response 





Figure 3 Schematic representation of iontophoretic delivery of vasoactive substances. 
Iontophoresis delivers charged pharmacological agents in solution to a localised area of skin by 
applying an opposing electrical current. Laser Doppler technology in combination with iontophoretic 
application of vasoactive substances to the skin allows study of aspects of the vasodilatory capacity 
of dermal vessels. Traditionally ACh and SNP are used to provoke endothelium-dependant and 
endothelium-independent vasodilation respectively51. 
 
Figure 4a Acquisition of SDF images. 
Hand held microscopes use side-stream dark field imaging to produce high-contrast real-time videos 
of the sublingual vessels 
 
Figure 4b. Example of sublingual microcirculation as visualised using SDF imaging. 
SDF is based on the principle that scattered green light is absorbed by haemoglobin in red blood 
cells, therefore any vessels containing RBCs can be visualised using this technique.  These images can 
be used to assess; vessel density, perfusion indices and heterogeneity 45, 46. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
